Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 15, 2001, Pages 8-15

  Berry, William ^a   Dakhil, Shaker ^a   Gregurich, Mary A ^a   Asmar, Lina ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOCETAXEL; HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; HUMAN; HYPERGLYCEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; SEPSIS;

EID: 0034789841     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.26893     Document Type: Article

References (22)

1. Cancer statistics 2000
2. Prostate cancer, incidence, management and outcomes
3. Chemotherapy in advanced prostate cancer
4. Chemotherapy for hormone refractory prostate cancer
5. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
6. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
7. Paclitaxel in the treatment of hormone-refractory prostate cancer
8. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer
9. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma
10. Phase 1 trial of docetaxel with estramustine in androgen-independent prostate cancer
11. Weekly administration of docetaxel (Taxotere): Summary of clinical data
12. Phase I trial of weekly paclitaxel in advanced lung cancer
13. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
14. Recent progress in the clinical development of docetaxel (Taxotere)
15. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
16. Nonparametric estimation from incomplete observations
17. Evaluation of survival data and two new rank order statistics arising in its consideration
18. Phase II trial of weekly docetaxel (Taxotere) in hormone refractory metastatic prostate cancer (HRPC)
19. Dose-dense weekly docetaxel (Taxotere) in metastatic breast cancer
20. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
21. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
22. Docetaxel (Taxotere) administered in weekly schedules